Abstract Number: 3050 • 2015 ACR/ARHP Annual Meeting
Evaluation of Olfactory Function in Behcet’s Disease
Background/Purpose: Behçet’s disease (BD) is a chronic, relapsing type of vasculitis of unknown etiology, characterized by oral and urogenital ulcers and ocular inflammation with cutaneous,…Abstract Number: 3051 • 2015 ACR/ARHP Annual Meeting
Bronchial Artery Enlargement May Cause Recurring Hemoptysis in Behçet’s Syndrome Patients with Pulmonary Artery Involvement Despite Response to Treatment
Background/Purpose: Hemoptysis is the most frequent and feared symptom of pulmonary artery involvement (PAI) in Behçet’s syndrome (BS). Some BS patients with PAI experience recurrent…Abstract Number: 3052 • 2015 ACR/ARHP Annual Meeting
Budd-Chiari Syndrome in Behçet’s Disease:a Retrospective Multicenter Study
Background/Purpose: Budd-Chiari syndrome (BCS), or hepatic venous outflow obstruction, is a rare and serious complication of Behçet's disease (BD). The aim of this study was…Abstract Number: 3053 • 2015 ACR/ARHP Annual Meeting
Patients Treated for Behcet Syndrome in the US Have Higher Disease Activity Scores at Presentation If They Fulfill ISG Criteria and If They Are Females, However Have Less Severe Disease Overall
Background/Purpose: Diagnosis of Behcet’s syndrome (BS) is based on clinical signs and symptoms, without the use laboratory or imaging tests and the most commonly used…Abstract Number: 3054 • 2015 ACR/ARHP Annual Meeting
Takayasu’s Arteritis Associated with Behçet’s Syndrome: A Case Series of 8 Patients
Background/Purpose: Takayasu's arteritis (TA) and Behçet's syndrome (BS) are both systemic vasculitis of an unknown etiology, each with unique involvement pattern. TA affects aorta and…Abstract Number: 3055 • 2015 ACR/ARHP Annual Meeting
Evaluation of Plasma Pentraxin-3 Level in Patients with Takayasu’s Arteritis
Background/Purpose: Assessment of disease activity is one of the major difficulties in patients with TAK during follow-up. To date, no biomarker is universally accepted to…Abstract Number: 3056 • 2015 ACR/ARHP Annual Meeting
Increased Circulating Th17 Cells, Serum IL-17 and Serum IL-23 in Takayasu’s Arteritis
Background/Purpose: The immune mechanisms underlying Takayasu’s arteritis (TA) are not clear. Expanded Th17 T cell subset has been demonstrated in Giant Cell Arteritis. Gamma delta…Abstract Number: 3057 • 2015 ACR/ARHP Annual Meeting
Can We Differentiate Takayasu’s Arteritis from Atherosclerosis Using Carotid Artery Doppler Usg?
Background/Purpose: Clinicians can have difficulty in making differential diagnosis between Takayasu and atherosclerosis. This is especially true when laboratory evaluations and FDG PET are inconclusive.…Abstract Number: 3058 • 2015 ACR/ARHP Annual Meeting
NMR-Based Metabolomics Provides New Insights into the Inflammatory Processes in Takayasu Arteritis
Background/Purpose: Takayasu Arteritis (TA), a large vessel disease of unknown aetiology, is the orphan of the inflammatory vasculitides with no evidence base for therapy. It…Abstract Number: 3059 • 2015 ACR/ARHP Annual Meeting
Abnormal Body Composition in Takayasu Arteritis Patients: Role of Inflammatory Cytokines and Adipokines
Background/Purpose: Chronic inflammatory conditions including rheumatic diseases may alter body composition, especially lean and fat mass. In this process, adipokines and inflammatory cytokines appear to…Abstract Number: 3060 • 2015 ACR/ARHP Annual Meeting
The Assessment of Disease Activity in Takayasu Arteritis; Six Years Experience from a Single Center
Background/Purpose: The aim of this study is to analyze the activity parameters that affect the physicians global opinion (PGO) in TA. Methods: The data of…Abstract Number: 3061 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Refractory Takayasu Arteritis. a Multicenter Study
Background/Purpose: Takayasu arteritis (TA) is often refractory to corticosteroids and traditional immunosuppressive agents. Interleukin (IL)-6 plays an important role in the pathogenesis of TA. Tocilizumab…Abstract Number: 3062 • 2015 ACR/ARHP Annual Meeting
Frequency, Presentation and Outcome of Takayasu Arteritis in Western Australia
Background/Purpose: Takayasu Arteritis (TAK) is a systemic large-vessel vasculitis that mostly affects women of childbearing age. The worldwide incidence of TAK varies due to genetic…Abstract Number: 3063 • 2015 ACR/ARHP Annual Meeting
Ocular Findings and Ocular Blood Flow Changes in Takayasu Arteritis: A Subclinical Reduction in Blood Flow with a Milder Clinical Course of Retinopathy
Background/Purpose: Ocular involvement in Takayasu arteritis (TAK) mainly arises due to complications related with altered ocular blood flow or side effects of the treatments. In…Abstract Number: 3064 • 2015 ACR/ARHP Annual Meeting
Cardiac Manifestation of Takayasu Arteritis
Background/Purpose: To explore cardiac manifestation of Takayasu arteritis and independent risk factor. Methods: We retrospectively analyzed manifestations and helpful tests in 55 TA patients. …
ACR Meeting Abstracts